LUND, SWEDEN--(MARKET WIRE)--Jul 23, 2008 -- Sven Andréasson has notified the Board of his wish to resign from the position as President & CEO of Active Biotech AB.
Sven Andréasson has been the company’s CEO since 1999 and under his leadership Active Biotech has been transformed from a combined vaccine and research company into a company focused on development of novel pharmaceuticals for treatment of cancer and autoimmune diseases.
The Board of Active Biotech AB has today decided to appoint Tomas Leanderson to become the new President & CEO. Tomas Leanderson has been the CSO for Active Biotech since 1999 (www.activebiotech.com).
Sven Andréasson will remain as CEO until September 1st 2008.
For further information please contact;
Mats Arnhög Chairman of the Board Telephone: +46 8 545 037 70 Mobile: +46 705 91 50 96
Lund, July 23, 2008
About Active Biotech
Active Biotech AB (OMX NORDIC: ACTI), headquartered in Sweden, is a biotechnology company with R&D focus on autoimmune/inflammatory diseases and cancer. Projects in pivotal phase are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer targeted therapy, primarily renal cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer, 57-57 for SLE and RhuDex® for RA. Please visit www.activebiotech.com for more information.
Active Biotech is required under the Securities Markets Act to make the information in this press release public. The information was submitted for publication at 8:30 a.m. CET on July 23, 2008.
Active Biotech AB PO Box 724, 220 07 Lund Sweden Tel +46 (0)46-19 20 00 Fax +46 (0)46-19 20 50
Copyright © Hugin AS 2008. All rights reserved.
Contact:
Source: Active Biotech
